IRVINE, Calif. and COLUMBIA, Md., March 10 /PRNewswire-FirstCall/ -- CalbaTech, Inc. , an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and services to the research market for biotech and pharmaceutical companies and to academic institutions, said today that its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, manufactures Yeast Nitrogen Glucose.
And what is the importance of that? The YNG media is being used by a National Institutes of Health laboratory and scientists there have reported in the American Society for Microbiology’s research publication that they have developed a synthetic antifungal that can combat yeast infections, such as Candidaisis, which can plague immuno-compromised pediatric patients as the result of cancer therapy.
“This is a day in the life of K-D Medical, a primary vendor to the National Institutes of Health, which also currently sells its full line of molecular biology products to Universities, Research Centers and major Pharmaceutical companies nationwide,” said John Powers, President. “While we may not produce products that directly lead to headlines about cures for diseases, we produce the bacterial and yeast growth media, the microbiological buffers and reagents that lead to major advances in science in public health. For instance, we are very involved in the research involving anthrax, which is feared to be a possible biological weapon of choice for terrorists.”
“This is an excellent example of the diversity and strengths K-D Medical brings to CalbaTech and we are very bullish on our wholly owned subsidiary’s business strategy,” said James DeOlden, CEO of CalbaTech.
About K-D Medical, Inc.
K-D Medical, (http://www.kdmedical.com), located in the heart of the Maryland Biotech Corridor, is one of the nation’s leading manufacturers of microbiological culture media and other research reagents. K-D Medical’s products are used in drug discovery, microbiology labs and biopharmaceutical production. The Company is headquartered in Columbia, Maryland.
About CalbaTech
CalbaTech, Inc. is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions. Its family of companies includes Lifestem, Inc., which offers the Stem Cell MicroBank(TM) Service for the collection of healthy adult stem cells for storage for potential future therapeutic use, K-D Medical, and Molecula (http://www.molecula.com), which develops and sells numerous reagents for cell transfection, DNA and RNA purification, and protein and gene expression. It is involved in some of the most advanced current scientific research involving gene function solutions with RNAi technology.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick@eandecommunications.com
Note: Certain statements in this news release may contain “forward- looking” information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
CalbaTech, Inc.
CONTACT: Paul Knopick of E&E Communications, +1-949-707-5365,pknopick@eandecommunications.com, for CalbaTech, Inc.
